Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Breast Neoplasms
  • Carcinoma
  • Deoxycytidine
  • Fluorouracil
  • Models, Biological
  • Prodrugs

abstract

  • As predicted by mathematical modeling, capecitabine dosing for 7 days followed by a 7-day rest is well tolerated. Efficacy of this schedule is being determined in a phase II clinical trial in patients with advanced breast cancer.

publication date

  • September 15, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.13.8388

PubMed ID

  • 18398145

Additional Document Info

start page

  • 1797

end page

  • 802

volume

  • 26

number

  • 11